Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vopratelimab and Ipilimumab in Advanced NSCLC or Urothelial Cancer
NCT03989362Phase 2Completed
- Sponsor
- Jounce Therapeutics
- Start
- Jun 2019
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of vopratelimab in non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), sponsored by Jounce Therapeutics. Started Jun 2019; status: completed.
02
Drugs
vopratelimab
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03989362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989362.